Positive allosteric modulation of the mu-opioid receptor (MOPr), the site of action of all clinically used opioids, represents a potential approach for the management of pain. We recently reported on positive allosteric modulators of MOPr (mu-PAMs), a class A G protein coupled receptor (GPCR). This study was designed to examine the mechanism of allostery by comparing the degree to which opioid ligand structure governs modulation. To do this we examined the interaction of the mu-PAM, BMS-986122, with a chemically diverse range of MOPr orthosteric ligands. Generally, for full agonists BMS-986122 enhanced the binding affinity and potency to activate G protein with no alteration in the maximal effect. In contrast, lower efficacy agonists including morphine were insensitive to alterations in binding affinity and showed little to no change in potency to stimulate G protein. Instead, there was an increase in maximal G protein stimulation. Antagonists were unresponsive to the modulatory effects of BMS-986122. Sodium is a known endogenous allosteric modulator of MOPr and alters orthosteric agonist affinity and efficacy. The sensitivity of an orthosteric ligand to BMS-986122 was strongly correlated with its sensitivity to NaCl. In addition, BMS-986122 decreased the ability of NaCl to modulate agonist binding in an allosteric fashion. Overall, BMS-986122 displayed marked probe dependence that was based upon the efficacy of the orthosteric ligand and can be explained using the Monod-Wyman-Changeux two-state model of allostery. Furthermore, disruption of the Na + ion binding site may represent a common mechanism for allosteric modulation of class A GPCRs.
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endogenous opioids | opiates | GTPgammaS | ligand binding | receptor states T he mu-opioid receptor (MOPr) is the site of action of all clinically used opioid drugs. MOPr is a class A G proteincoupled receptor (GPCR) that activates heterotrimeric Gi/o proteins. Clinically used opioid agonists bind to the orthosteric site on MOPr and although they are efficacious at causing pain relief, have a number of unwanted side effects resulting from direct MOPr activation. We have recently discovered and presented a preliminary characterization of positive allosteric modulators of MOPr (mu-PAMs) and are currently pursuing the idea that mu-PAMs could be a viable way to manage pain (1, 2) . The ligand BMS-986122 (Fig. S1 ) represents the most active mu-PAM currently identified. It was discovered in a high-throughput screen for its ability to enhance the recruitment of β-arrestin to MOPr by the agonist endomorphin-1. Although having little agonist activity on its own, this modulator has the ability to enhance the affinity, potency, and/or maximal response of MOPr agonists. In the same systems, BMS-986122 has no activity when the delta opioid receptor (DOPr) is expressed, indicating the importance of MOPr for BMS-986122 activity.
The study of allosteric modulation of GPCRs has recently gained momentum (3) and represents a relatively unexplored avenue for drug development (4, 5) . Allosteric modulators have been discovered for several GPCRs including the muscarinic, cannabinoid, and metabotropic glutamate receptors (6-8) with a growing body of in vitro and in vivo literature describing allostery at GPCRs (9) (10) (11) . In contrast, apart from our initial description of mu-PAMs, very little is known about allostery at MOPr.
Allosteric modulators exhibit probe dependence, meaning they show disparate effects depending on the agonist bound to the orthosteric site (12) . A striking example of this is LY2033298, a PAM of the muscarinic acetylcholine receptors M2 and M4. LY2033298 increases the affinity of the agonist oxotremorine, while having no effect on the binding of the agonists pilocarpine and McN-A-343 (13) . Currently, it is not known if all opioid agonists are equally sensitive to the PAM effect of BMS-986122, nor the mechanism underlying the allosteric modulation. Our initial characterization showed that BMS-986122 causes a shift in the potency of the agonist DAMGO ([D-Ala 2 , N-MePhe 4 , Gly-ol]-enkephalin), but increases the maximal stimulation of G protein by morphine (1) . Opioid ligands are extremely diverse, ranging from the 31-amino acid endogenous peptide β-endorphin to small alkaloids like morphine. Therefore, this study sought to answer two questions: (i) does BMS-986122 show probe dependence for the orthosteric ligand? And (ii) if probe dependence is seen, what is the mechanistic basis for this?
To address these questions we examined the effect of BMS-986122 on the MOPr properties of a wide range of opioid ligands from endogenous peptides to small molecules (Fig. S2) . The results reveal that the PAM effects of BMS-986122 are dependent on the efficacy of the orthosteric ligand and not on the structure per se. We find a strong correlation between the positive action of BMS-986122 and the negative action of Na + ions
Significance
Morphine and related compounds are the gold standard for the management of pain. Such drugs bind to the orthosteric site on the mu-opioid receptor (MOPr), a G protein-coupled receptor (GPCR to inhibit agonist binding. Moreover, we also show that BMS-986122 allosterically inhibits the ability of Na + ions to reduce agonist binding. The PAM effect of BMS-986122 can consequently be explained by an inhibition of the ability of Na + ions to stabilize the inactive state of the receptor, thereby allowing the receptor to shift to an active conformation. Thus, the mechanism of positive allosteric modulation can be simply explained by the two-state Monod-Wyman-Changeux model of allosterism (14) .
Results
We first investigated the effects of a maximally effective concentration (10 μM; ref. 1) of BMS-986122 on the MOPr activity of a range of endogenous opioid peptides (Fig. S2A) . Using cell membrane homogenates prepared from C6 glioma cells stably expressing MOPr (C6MOPr) (15), we performed radioligand competition binding assays using 3 H-diprenorphine (DPN, an opioid antagonist) in the presence of GTPγS and NaCl to generate an inactive receptor state known to predominate in native membranes (16, 17) . As shown in Fig. 1A and Table 1 , BMS-986122 caused an approximate sixfold enhancement in the affinity of both methionine-enkephalin (Met-Enk) and leucineenkephalin (Leu-Enk). A similar increase in affinity was seen for the smaller putative endogenous peptide endomorphin-1 (18) . In addition to enhancing its affinity to bind MOPr, BMS-986122 caused a leftward shift in the concentration-response for MetEnk to activate G protein, with no alteration in the maximal response (Emax), as measured by GTPγ 35 S binding in membrane homogenates (Fig. 1C and Table 2 ); an effect also seen with Leu-Enk and endomorphin-1 ( Table 2 ). The endogenous opioid β-endorphin, a much larger 31-amino acid peptide, was also modulated by BMS-986122 with rightward shifts in both the affinity (fourfold; Table 1 ) and potency (sixfold; Table 2 ) to activate G protein.
Because we had previously seen that BMS-986122 increased the maximal G protein activation by morphine (1), we determined the modulation of opioid affinity, potency, and maximal agonist effect of this small molecule MOPr agonist. There was no shift in the affinity of morphine to bind MOPr in the presence of BMS-986122 ( Fig. 1B and Table 1 ). Even at 30μM BMS-986122, a concentration approaching the limits of solubility, there was still no enhancement of morphine affinity [ Fig. S3 ;
. In contrast to this lack of effect on affinity, BMS-986122 did alter the ability of morphine to activate G protein. There was a small 2.9-fold decrease in the potency (EC 50 ), but the most striking effect was a significant increase in the degree of maximal activation. In the presence of BMS-986122, morphine was able to activate G protein to nearly the same extent as the full agonist DAMGO ( Fig. 1D and Table 2 ). Moreover, the rate at which DAMGO activated G protein was unchanged in the presence of 10 μM BMS-986122 whereas the rate of morphine-activated G protein was enhanced (Fig. 1E) .
We hypothesized that the disparate effects on orthosteric ligand binding seen with BMS-986122 might be explained by the structure of the ligand: peptides versus small molecules. All of the endogenous ligands tested are large, flexible peptides, whereas morphine is a small, rigid molecule. To address this possibility, we measured the effect of BMS-986122 on additional small molecule MOPr agonists that are structurally distinct from morphine, namely buprenorphine, fentanyl, methadone, and loperamide as well as the antagonist naloxone (Tables 1 and 2 and Fig. S2B ). Buprenorphine behaved like morphine, showing no increase in binding affinity for MOPr or potency in the GTPγ 35 S assay, but a marked concentration-dependent enhancement in maximal effect (Fig. S4 ). With The rate of DAMGO-stimulated GTPγ 35 S was unchanged (vehicle: 21.5 ± 1.0 cpm/min; BMS-986122: 20.8 ± 0.7 cpm/min), whereas the rate of morphinestimulated GTPγ 35 S was enhanced from 11.5 ± 0.7 cpm/min (vehicle) to 18.1 ± 0.5 cpm/min in the presence of BMS-986122. All plotted points are means ± SEM of three to five independent experiments, each in duplicate. S binding. Conversely, for the small molecule (RS)-methadone, there was a 10.9-fold shift in the MOPr binding affinity ( Fig. 2A and Table 1 ) and a large (11.5-fold) shift in the potency of (RS)-methadone to activate G protein, with no increase in the maximal effect ( Fig. 2B and Table 2 ). Hill slopes of binding and GTPγ 35 S assay data for all compounds were not significantly different from 1.0. We further characterized the effect of BMS-986122 on (RS)-methadonemediated G protein activation by performing a series of concentration-response curves in the presence of increasing levels of BMS-986122 (Fig. 2C) . Analyses of these curves using the allosteric ternary complex model afforded an alpha (α) value for functional cooperativity between (RS)-methadone and BMS-986122 of 18.4 and an affinity (Kb) of 1.7 μM. This contrasts with our previously published cooperativity value of 8 for the interaction between endomorphin-1 and BMS-986122 recruitment of β-arrestin (1). For loperamide, there was a similar 15-fold shift in affinity and a 9.5-fold shift in the potency (Tables 1 and 2) .
The above experiments used racemic methadone. The (R)-isomer has a higher affinity for MOPr and a higher analgesic potency than the (S)-isomer (19, 20) . We therefore examined whether the differential binding of the isomers to the MOPr affected the response to BMS-986122. The affinities of the individual isomers for MOPr as well as the racemate were all enhanced in the presence of BMS-986122 (Table 1 ). In the GTPγ 35 S assay for (R)-methadone, there was an 8.8-fold shift in potency in the presence of BMS-986122, with no change in maximal G protein stimulation. In contrast (S)-methadone, which is a partial agonist, responded to the presence of BMS-986122 with a sixfold shift in potency as well as an enhancement of the maximal stimulation. There was no effect of BMS-986122 on the affinity of the antagonist naloxone for MOPr (Table 1) , nor did BMS-986122 impart any agonist activity to naloxone ( Table 2) .
The above findings suggest that it is the degree of agonist efficacy of the orthosteric ligands rather than their chemical structure that governs the response to BMS-986122 and so the observed probe dependence. Sodium ions are known to reduce the affinity of agonists to bind to GPCRs, including the MOPr (21-23), by stabilizing an inactive state of the receptor (24) (25) (26) . Agonists vary in their response to Na + ions such that sensitivity to Na + ions generally correlates with the degree of intrinsic activity, with a continuum from antagonists that are insensitive to Na + ions to full agonists that are the most sensitive. Because this finding matches the responsiveness to BMS-986122, we hypothesized that there would be a correlation between the sensitivity of a ligand to the mu-PAM and the sensitivity of a ligand to the presence of Na + ions. Competition binding curves for orthosteric ligands were performed in Tris buffer in the absence or presence of NaCl/GTPγS to calculate the ratio of binding affinity (as pKi values) to active and inactive states of MOPr. Under both conditions competition binding curves with Hill slopes not significantly different from one were obtained for all compounds (Fig.  S5) . pKi values under the two conditions were then compared with the shift in affinity (Fig. 3A) or potency (Fig. 3B ) of the orthosteric ligand caused by 10 μM BMS-986122. We observed a strong correlation between an orthosteric ligand's loss of binding affinity in the presence of Na + /GTPγS and its increased affinity or potency in the presence of BMS-986122. As expected, there was a relationship between the shift in potency and affinity of orthosteric ligands caused by BMS-986122 (Fig. S6) .
To analyze whether Na + ions and BMS-986122 were antagonistic, we investigated the ability of BMS-986122 to inhibit the effect of Na + ions on agonist binding. As expected NaCl showed a concentration-dependent inhibition of DAMGO binding, determined as the inhibition of an EC 50 concentration of DAMGO (10 nM) to displace 3 H-DPN (0.2 nM) (Fig. 3C ). This gave an inhibitory concentration 50 (IC 50 ) value for NaCl of 6 ± 1 mM. Addition of BMS-986122 resulted in a concentration-dependent rightward shift of the IC50 of NaCl to 16 ± 2 mM in the presence of 3 μM BMS-986122 and 36 ± 8 mM in the presence of 10 μM BMS-986122. This effect was saturable as the curve failed to shift any further in the presence of 30 μM BMS-986122 (Fig. 3C) .
Finally, to confirm a role for Na + ions we examined the ability of BMS-986122 to alter etorphine binding and activity. Etorphine (Fig. S2B) is a potent full agonist at MOPr, but is relatively insensitive to Na + /GTP (K i = 0.18 ± 0.03 nM in Tris and K i = 2.4 ± 0.3 nM with Na + /GTPγS) compared with other full agonists (16). We therefore hypothesized that etorphine would be GTPγS assay was performed as described in Methods. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control (vehicle) data by Student t test. Data shown are means ± SEM of three to five independent experiments each in duplicate. d.n.s., did not stimulate.
† Maximal values relative to the stimulation observed with 10 μM DAMGO.
less sensitive to BMS-986122. Indeed, BMS-986122 caused no shift in the affinity of etorphine (Table 1 ). In GTPγ 35 S binding assays, there was also no significant shift in potency and no alteration in the level of maximal stimulation ( Table 2) .
Discussion
In this study we show that the mu-PAM BMS-986122 exhibits marked probe dependence across a variety of structurally diverse agonists acting at the orthosteric site on MOPr. The sensitivity of orthosteric ligands to BMS-986122 correlated with the ratio of agonist affinities for active and inactive states of the receptor defined by the absence or presence of Na + ions and guanine nucleotide and was consistent with the hypothesis that probe dependence of BMS-986122 is defined by the efficacy of the orthosteric agonist. The effects of BMS-986122 are in line with the Monod-Wyman-Changeux two-state model of allosterism (14, 27 ) involving a single active state, bound to G protein, and single inactive receptor state, uncoupled from G protein and stabilized by Na + ions. BMS-986122 favors the active state, opposes the action of Na + ions, and therefore positively modulates the properties of the orthosteric agonist.
Although the degree of effect varied, BMS-986122 enhanced the affinity and potency of all endogenous opioid peptides tested and none showed any enhancement of maximal G protein activation. We initially hypothesized that the 31-amino acid β-endorphin may be a bitopic ligand, capable of binding to both the orthosteric site as well as the allosteric site (for review, see ref. 28 ). Thus, we predicted that β-endorphin would compete with BMS-986122 as well as with 3 H-DPN for binding to MOPr. However, BMS-986122 affected β-endorphin in a manner similar to other endogenous ligands, suggesting that it is not bitopic, at least for the allosteric site occupied by BMS-986122.
In contrast to the peptides, there were differences seen with small molecule MOPr agonists, indicating orthosteric probe dependence. Morphine, buprenorphine, and fentanyl showed an increase in maximal ability to stimulate GTPγ 35 S binding with little or no change in potency or affinity in the presence of BMS-986122. Opioid peptides have a message and address sequence (29, 30) and occupy more of the MOPr binding pocket than smaller organic molecules (31) which could explain their different sensitivities to BMS-986122. However, our findings are not simply a matter of chemical structural differences in terms of peptide versus small molecules because (R)-methadone and loperamide were sensitive to BMS-986122 in the same ways as the endogenous peptides. Indeed, the allosteric action of BMS-986122 on these compounds was much greater than for the peptides.
Morphine, as well as fentanyl, buprenorphine, and (S)-methadone have reduced efficacy compared with the endogenous peptides and (R)-methadone or loperamide. We have previously reported that binding of the opioid antagonist DPN was unaffected by BMS-986122 (1) and have now demonstrated a lack of modulation of the opioid antagonist naloxone. Thus, a rational explanation for our findings is that the observed probe selectivity is dependent on agonist efficacy. Table 3 lists the intrinsic efficacy of the opioid compounds examined, determined by the method of Ehlert (32) using values for agonist affinity determined in the presence or absence of NaCl/GTPγS and agonist potency in the GTPγ 35 S assay. The compounds with efficacy greater than or equal to β-endorphin [namely etorphine, Leu-Enk, loperamide, Met-Enk, (RS)-and (R)-methadone, endomorphin 1], all behaved similarly in their response to BMS-986122 with an increase in potency and ligand affinity, but no change in maximal response. In contrast, the lower efficacy agonists showed an increase in maximal effect with minimal alteration in potency or affinity, resulting in an increase in intrinsic efficacy (Table 3) . With morphine we also demonstrated an increase in the rate of G protein activation, a property associated with ligand efficacy (33) . Finally (S)-methadone, that has an efficacy value between that of morphine and DAMGO, showed a shift in potency and an increase in maximal effect.
In a simple two-state model of GPCR activation, receptors are hypothesized to exist in conformational states that differ dramatically in their affinity for orthosteric agonists. Agonists have higher affinity for the active, G protein bound state and preferentially stabilize this conformation, thus propelling agonistinduced activation of G protein and downstream cellular responses (34, 35) . The inactive receptor state has lower affinity for orthosteric agonists and is stabilized in the presence of Na + ions as well as guanine nucleotides that drive uncoupling of receptor and G protein. The differential affinity of orthosteric agonists used in this study for inactive and active MOPr states varied, but showed a strong correlation with their relative sensitivity to BMS-986122 and with their potency to stimulate GTPγ 35 S binding. Thus, BMS-986122 appears to shift the equilibrium toward the active receptor state thereby modulating the activity of the orthosteric agonists differentially, depending on their efficacy, an action that is opposite to the effects of Na + ions (23) . The action of BMS-986122 on maximal response of the lower efficacy agonists is also in line with a two-state model of GPCR function. Using the idea that efficacy is based upon an agonist's ability to shift the equilibrium of receptors toward an active state we would expect BMS-986122, by stabilizing an active receptor state, to enhance the efficacy of partial agonists. The appropriateness of the two-state model of allosterism to explain the probe dependence of BMS-986122 at MOPr mirrors the action of the M 1 muscarinic acetylcholine receptor modulator BQCA (benzylquinone carboxylic acid), which enhances the potency of orthosteric ligands or their maximal response depending on the efficacy requirements of the signaling assay (27) .
If a two-state model does explain the action of BMS-986122 then we should expect to see agonist activity of the modulator even in the absence of orthosteric agonist (27) . BMS-986122 alone fails to activate G protein to a detectable level as measured by the GTPγ 35 S assay, even with a lowered Na + concentration to increase apparent efficacy (Fig. S7) (36) . Downstream of G proteins, MOPr orthosteric agonists inhibit adenylate cyclase (AC), a response that is more sensitive to lower efficacy compounds, due to increased amplification (37) . At high concentrations, BMS-986122 does inhibit AC (1), thus confirming the appropriateness of the two-state model. In addition, we would predict BMS-986122 to have activity at even more amplified downstream signaling pathways (27) .
An apparent anomaly to the hypothesis that probe dependence is based on orthosteric ligand efficacy and can be explained by a two-state model is that etorphine shows no cooperativity with BMS-986122, and is relatively insensitive to Na + ions, yet this compound is a highly efficacious MOPr agonist (Table 3) . Biophysical studies with the β2-adrenergic receptor have shown that agonists destabilize the receptor, but the receptor exists in a variety of conformationally heterogeneous states that are not fully stabilized unless G protein is bound (38) . Thus, it is feasible that etorphine promotes a state that has very high affinity for G protein, but enriches this population to a lesser extent than other agonists.
Further support for the two-state model comes from the relationship between BMS-986122 and Na + ions. High-resolution X-ray structures of several class A GPCRs (25) , including the DOPr (24) , have identified the Na + site as a Na + -H 2 O cluster in a cavity in the middle of the 7-transmembrane (TM) helices. This cavity in the DOPr is formed by side chains of 16 residues distributed across TM domains 2, 3, 6 and 7 and is fully conserved in the MOPr (24) . Comparison of inactive and active GPCR structures and molecular dynamics simulations performed with the adenosine A2A receptor show that agonist binding causes molecular rearrangements that are not compatible with concurrent Na + binding (25) . In particular, the addition of agonist dramatically reduces the size of the binding pocket for the Na + -H 2 O cluster. BMS-986122 decreased the potency of Na + ions to inhibit binding of the agonist DAMGO and there was a strong correlation between the opposite effects of the BMS-986122 and Na + /GTP on opioid ligands. Thus, the binding of both BMS-986122 and Na + to MOPr is incompatible. We conclude that BMS-986122 favors the active receptor conformation with disruption of the Na + -H 2 O cluster binding pocket and this explains its PAM activity. The interaction between Na + and BMS-986122 could be through direct competition, for example as with the diuretic amiloride (39), or indirectly through an allosteric interaction. However, the evidence favors an allosteric mechanism for several reasons. First, BMS-986122 does cause a small increase in agonist affinity in the absence of Na + ions (1) suggesting it can stabilize an active receptor conformation. Second, the same degree of shift in the inhibitory effect of NaCl on DAMGO binding is seen with both 10 μM and 30 μM BMS-986122, suggesting saturation is reached as expected for allosterism, rather than the surmountable parallel shifts expected if the antagonism were competitive (40) . Third, the Na + -H 2 O cluster binding pocket is conserved between MOPr and DOPr (24) and indeed across all Class A GPCRs (26) , yet the PAM activity of BMS-986122 is selective for MOPr over DOPr (1) .
In conclusion, this study further confirms the use of the MonodWyman-Changeux two-state model of allosterism as the simplest mechanism to explain PAM activity at GPCRs (27) . Furthermore, the results directly relate the action of a small molecule PAM to interference with Na + binding at a GPCR. Disruption of the Na + binding pocket during receptor activation may be a general mechanism for allosteric modulation across many class A GPCRs that have a conserved Na + -H 2 O cluster binding pocket. For example, the CB1 receptor PAM ORG27569 and the M 1 receptor PAM BQCA both enhance the high affinity state of their respective receptors Tables 1 and  2 according to the method of Ehlert (32) as described in Methods. (27, 41) . This may, however, not be true for all agonists, in particular, those whose affinity is less sensitive to Na + ions such as etorphine, or receptors such as the β1 adrenergic receptor where Na + does not appear to be involved in the transition from inactive to active states (42) . Nonetheless interference with the stability of the Na + -H 2 O binding pocket of GPCRs may be a generally applicable mechanism that provides a basis for the discovery of novel modulators and the identification of potential endogenous modulators (for review, see ref. 43 ).
